ESPR
NASDAQ HealthcareEsperion Therapeutics, Inc. - Common Stock
Drug Manufacturers - Specialty & Generic
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
๐ Market Data
| Price | $3.11 |
|---|---|
| Volume | 182,012,711 |
| Market Cap | 800.53M |
| Beta | 1.170 |
| RSI (14-Day) | 74.1 Overbought |
| 200-Day MA | $2.79 |
| 50-Day MA | $2.56 |
| 52-Week High | $4.18 |
| 52-Week Low | $0.69 |
| Forward P/E | 12.82 |
| Price / Book | -2.53 |
๐ฏ Investment Strategy Scores
ESPR scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (89/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ช Falling Knife (18/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ESPR in your text
Paste any article, transcript, or post โ the tool will extract ESPR and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.